Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML

Lina Benajiba, Florence Wagner, PhD, Linda Ross, PhD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Jennifer Gale, Jen Pan, PhD, Yan-Lin Zhang, PhD, Joshua Sacher, PhD, Michel Weiwer, PhD, Richard M. Stone, MD, Edward Holson, PhD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 870.

https://doi.org/10.1182/blood.V126.23.870.870

Published: 2015

Journal Articles

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

Mark A. Murakami, MD MA, Alexandra N. Christodoulou, M.S., Amanda L Christie, B.S., Tiffany DeSouza, B.S., Abner Louissaint, Jr., MD PhD, Una Vojinovic, B.S., Raphael Koch, MD, Loretta S. Li, MD, Scott P. Kallgren, PhD, Prakash Rao, PhD, Johannes Köster, PhD, Raga Vadhi, M.S., Eilene Duberow, B.S., Elizabeth A. Morgan, MD, Hongjun Wang, Samia S. Ahmed, Katharine L. Majewski, Marina Konopleva, MD PhD, Jerome Tamburini, MD, PhD, Alejandro Gutierrez, MD, Michelle Kelliher, PhD, Julia Etchin, PhD, Irmela Jeremias, MD, Andrew P. Weng, MD PhD, Andrew L Kung, MD PhD, Andrew A Lane, MD PhD, Francine Garnache-Ottou, PhD, Shai Izraeli, MD Prof, Eric Jacobsen, MD, Ilene Galinsky, ANP, Richard M. Stone, MD, Marian H. Harris, MD PhD, David M. Dorfman, MD PhD, Jon C Aster, MDPhD, Henry Long, PhD, Lewis B. Silverman, MD, David M Weinstock, MD

Blood (2015) 126 (23): 3252.

https://doi.org/10.1182/blood.V126.23.3252.3252

Published: 2015

Journal Articles

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

Julia Etchin, PhD, Alla Berezovskaya, Amy Saur Conway, Weihsu Claire Chen, PhD, Erkan Baloglu, PhD, Yosef Landesman, PhD, William Senapedis, PhD, Joel Ellis, PhD, Dilara McCauley, PhD, Richard M. Stone, MD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Michael Kauffman, Sharon Shacham, Jean C.Y. Wang, MDPhD, A. Thomas Look, MD

Blood (2015) 126 (23): 326.

https://doi.org/10.1182/blood.V126.23.326.326

Published: 2015

Journal Articles

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

Blood (2015) 126 (23): 2549.

https://doi.org/10.1182/blood.V126.23.2549.2549

Published: 2015

Journal Articles

Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia

Andrew M. Brunner, MD, Donna S Neuberg, ScD, Seth A. Wander, MD PhD, Hossein Sadrzadeh, MD, Karen K. Ballen, MD, Philip C. Amrein, MD, Gabriela S. Hobbs, MD, Yi-Bin Chen, MD, Ashley M. Perry, BS, Christelle Joseph, Meghan E. Burke, Aura Y Ramos, Regina Silver, Ilene Galinsky, ANP, Sophia Adamia, PhD, Darrell Borger, PhD, Anthony J Iafrate, MD PhD, Richard M. Stone, MD, Amir T. Fathi, MD

Blood (2015) 126 (23): 2597.

https://doi.org/10.1182/blood.V126.23.2597.2597

Published: 2015

Journal Articles

Targeting MTHFD2 in Acute Myeloid Leukemia

Yana Pikman, MD, Alexandre Puissant, PhD, Gabriela Alexe, PhD, Andrew Furman, BA, Stacey Frumm, BA, Linda Ross, PhD, Liying Chen, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Caroline A Lewis, PhD, Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, ANP, Andrew L Kung, MD PhD, Matthew Vader Heiden, MD PhD, Michael T. Hemann, PhD, Versha Banerji, MD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 443.

https://doi.org/10.1182/blood.V126.23.443.443

Published: 2015

Journal Articles

Identification of CKMT1B As a New Target in EVI1-Positive AML

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Gabriela Alexe, PhD, Lina Benajiba, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 3674.

https://doi.org/10.1182/blood.V126.23.3674.3674

Published: 2015

Journal Articles

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Sophia Adamia, PhD, Patricia Toniolo, PhDcandidate, Amir T. Fathi, MD, Ilene Galinsky, ANP, Suiyang Liu, Katharine Yen, Hyeryun Kim Kim, Dongwei Zhu, Straley Kim, Martha Wadleigh, MD, David P. Steensma, MD, Ibiayi Dagogo-Jack, MD, Daniel J. DeAngelo, MD PhD, James D. Griffin, MD, Richard M. Stone, MD

Blood (2014) 124 (21): 1060.

https://doi.org/10.1182/blood.V124.21.1060.1060

Published: 2014

Journal Articles

Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium

Amir T. Fathi, MD, Daniel J DeAngelo, Kristen E. Stevenson, MS, Jonathan E. Kolitz, MD, Julie D. Asch, MD, Philip C. Amrein, MD, Eyal C. Attar, MD, David P. Steensma, MD, Martha Wadleigh, MD, Christine Connolly, Ilene Galinsky, ANP, Richard M. Stone, MD, Donna S. Neuberg, ScD, Karen K. Ballen, MD

Blood (2014) 124 (21): 3714.

https://doi.org/10.1182/blood.V124.21.3714.3714

Published: 2014

Journal Articles

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients

Blood (2013) 122 (21): 3928.

https://doi.org/10.1182/blood.V122.21.3928.3928

Published: 2013

Journal Articles

Small Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells and Cause Cytotoxicity

Helena Mistry, Ph.D., Grace Hsieh, M.D., Sara Buhrlage, Ph.D, Min Huang, Ph.D., Eunmi Park, Ph.D., Gregory Cuny, Ph.D., Ilene Galinsky, ANP, Richard M. Stone, MD, Nathanael S Gray, PhD, Kalindi Parmar, PhD, Alan D. D'Andrea, MD

Blood (2013) 122 (21): 2906.

https://doi.org/10.1182/blood.V122.21.2906.2906

Published: 2013

Journal Articles

A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)

Richard M. Stone, MD, Caitlin Driscoll, Ilene Galinsky, ANP, Martha Wadleigh, MD, David P. Steensma, MD, David Avigan, MD, Philip C. Amrein, MD, Suiyang Liu, James D. Griffin, MD, Steven L. McAfee, MD, Eyal C. Attar, MD, Karen K. Ballen, MD, Edward Fox, PhD, Daniel J. DeAngelo, MD, PhD

Blood (2012) 120 (21): 3627.

https://doi.org/10.1182/blood.V120.21.3627.3627

Published: 2012

Journal Articles

Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition

Blood (2012) 120 (21): 3583.

https://doi.org/10.1182/blood.V120.21.3583.3583

Published: 2012

Journal Articles

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

Sophia Adamia, PhD, Hervé Avet-Loiseau, MD, PhD, Jana Jakubikova, Suzan Lazo-Kallanian, John Daley, PhD, Laurence Lode, Ph.D, Ilene Galinsky, ANP, Richard M. Stone, MD, James D. Griffin, MD

Blood (2012) 120 (21): 652.

https://doi.org/10.1182/blood.V120.21.652.652

Published: 2012

Journal Articles

Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets

Sophia Adamia, Ph.D, Michal Bar-Natan, M.D, Benjamin Haibe-Kains, Ph.D, Hervé Avet-Loiseau, MD, PhD, Laurence Lode, Ph.D, Samuel Pevzner, Sigitas Verselis, PhD, Edward Fox, PhD, Ilene Galinsky, ANP, John Quackenbush, Ph.D, Richard M. Stone, MD, James D Griffin, MD

Blood (2011) 118 (21): 761.

https://doi.org/10.1182/blood.V118.21.761.761

Published: 2011

Journal Articles

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission

Blood (2011) 118 (21): 948.

https://doi.org/10.1182/blood.V118.21.948.948

Published: 2011

Journal Articles

MUC1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy

Dina Stroopinsky, PhD, Jacalyn Rosenblatt, MD, Heidi Mills, BA, Katarina Luptakova, MD, Brett Glotzbecker, MD, Baldev Vasir, PhD, Robin Joyce, MD, James Levine, MD, Dimitrios Tzachanis, MD, PhD, Jon E. Arnason, MD, Ilene Galinsky, ANP, Richard M. Stone, MD, Donald Kufe, MD, Yoram Reiter, PhD, David Avigan, MD

Blood (2011) 118 (21): 1883.

https://doi.org/10.1182/blood.V118.21.1883.1883

Published: 2011

Journal Articles

Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition

Dina Stroopinsky, PhD, Jacalyn Rosenblatt, MD, MSc, Keisuke Ito, MD, PhD, Li Yin, Hasan Rajabi, PhD, Baldev Vasir, PhD, Turner Kufe, Brett Glotzbecker, MD, Katarina Luptakova, MD, Heidi Mills, BA, Robin Joyce, MD, Dimitrios Tzachanis, MD, PhD, Vassiliki A Boussiotis, MD, PhD, James Levine, MD, Ilene Galinsky, ANP, Richard Stone, MD, Pier Paolo Pandolfi, MD, PhD, Donald Kufe, MD, David Avigan, MD

Blood (2010) 116 (21): 848.

https://doi.org/10.1182/blood.V116.21.848.848

Published: 2010

Journal Articles

Comparison of High Dose Chemotherapy with Autologous Stem Cell Rescue (ASCT) Versus Consolidation Chemotherapy for Patients < 60 with Cytogenetically Normal AML (CN-AML) and Flt3 ITD

Harshabad Singh, MBBS, Lillian Werner, Daniel J DeAngelo, MD, PhD, Philip C. Amrein, MD, Martha Wadleigh, M.D., Karen K Ballen, MD, Ilene Galinsky, ANP, Donna Neuberg, ScD, Edward Fox, Richard M Stone, M.D., Eyal C Attar, MD

Blood (2010) 116 (21): 3555.

https://doi.org/10.1182/blood.V116.21.3555.3555

Published: 2010

Journal Articles

Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML)

Sophia Adamia, Hervé Avet-Loiseau, Laurence Lodé, Michal Bar-Natan, Sigitas Verselis, PhD, Edward Fox, Ilene Galinsky, ANP, Philippe Moreau, Richard Stone, MD, James D. Griffin, MD

Blood (2010) 116 (21): 177.

https://doi.org/10.1182/blood.V116.21.177.177

Published: 2010

NARROW

Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia

Targeting MTHFD2 in Acute Myeloid Leukemia

Identification of CKMT1B As a New Target in EVI1-Positive AML

IDH1 Splicing Alterations in Patients with AML and Their Relationship to Blood 2HG Levels

Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients

Small Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells and Cause Cytotoxicity

A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)

Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission

MUC1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy

Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition

Comparison of High Dose Chemotherapy with Autologous Stem Cell Rescue (ASCT) Versus Consolidation Chemotherapy for Patients < 60 with Cytogenetically Normal AML (CN-AML) and Flt3 ITD

Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only